$DARE - $1.79. Float~14M. VOL 5.5M up 114% at 9:05 AM. MCap: $14M. Income: ($-14M). Cash: LOW. 52W range: $0.69 - $3.25. Catalyst: Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive. Daré may be entitled to up to $310 million in commercial milestone payments plus tiered royalties on net sales in the double-digits. Daré will receive an upfront payment and access to Bayer’s extensive clinical and market capabilities while retaining control over Ovaprene’s development and regulatory approval process. Ovaprene releases a locally acting, non-hormonal agent which impedes sperm motility and features a proprietary knitted polymer barrier to physically block sperm from entering the cervical canal.Ovaprene will be a first-in-category therapy for women seeking a hormone-free, self-administered and non-invasive birth control method. Comment: ON WATCH
  • 1